A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/395 (2006.01) A61K 31/517 (2006.01) A61K 31/519 (2006.01)
Patent
CA 2757730
The combination of an IGF-1R antagonist such as a humanized antibody and an anti-proliferative drug is described. In a preferred embodiment, the present invention describes the combination of an IGF-1R antibody and an anti-proliferative drug belonging to the EGFR-inhibitor class, which is preferably erlotinib. The combination according to the present invention is useful for the treatment of tumours, including IGF-1R and /or EGFR mediated or dependent tumours.
La présente invention concerne l'association d'un antagoniste de l'IGF-1R, tel qu'un anticorps humanisé, et un médicament antiprolifératif. Selon un mode de réalisation préféré, la présente invention concerne la combinaison d'un anticorps anti-IGF-1R et d'un médicament antiprolifératif appartenant à la catégorie des inhibiteurs de l'EGFR, de préférence l'erlotinib. Selon la présente invention, la combinaison est utile pour le traitement de tumeurs, notamment les tumeurs IGF-1R-dépendantes et/ou EGFR-dépendantes ou les tumeurs à médiation de l'IGF-1R et/ou de l'EGFR.
Chastain Michael
Kasibhatla Shailaja
Sathyanarayanan Sriram
Winter Christopher
Gowling Lafleur Henderson Llp
Merck Sharp & Dohme Corp.
LandOfFree
Combination therapy using an anti-egfr agent(s) and igf-1r... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination therapy using an anti-egfr agent(s) and igf-1r..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination therapy using an anti-egfr agent(s) and igf-1r... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1490180